Patterns of relapse in older women diagnosed with estrogen receptor (ER) –positive early-stage breast cancer (BC) treated with lumpectomy without adjuvant endocrine therapy (ET)
ConclusionPatterns of relapse in older women with ER-positive early-stage BC note that local relapse is the most common site of failure. In this study, we also observed a low risk of distant relapse among patients not receiving ET. These observations on relapse patterns suggest that older women with early-stage BC may derive more benefit from adjuvant RT alone and be spared the potential side effects of ET.
Psychiatric Services, Ahead of Print.
British Journal of Cancer, Published online: 10 December 2019; doi:10.1038/s41416-019-0662-8High-resolution imaging mass spectrometry combined with transcriptomic analysis identified a link between fatty acid composition of phosphatidylinositols and the immune checkpoint pathway at the primary tumour site of breast cancer
AbstractThe poly-(ADP-ribose) polymerase (PARP) inhibitors olaparib and talazoparib, have recently been approved for use in patients with metastatic breast cancer (BC) and germline BRCA 1 or 2 mutations due to improved progression-free survival compared to chemotherapy. An increasing number of clinical trials are evaluating the role of PARP inhibitors (PARPi) in BC, alone and in combination with other therapies (including immunotherapy), as well as in earlier stages of the disease. This review describes the unique mechanism of action of these drugs and puts into clinical context the results of pivotal clinical trials. We a...
ConclusionDirect-to-implant IBR after skin-sparing mastectomy is a viable option for breast cancer patients undergoing neoadjuvant chemotherapy.ResumenIntroducciónLa reconstrucción inmediata (RMI) tras mastectomía en pacientes que han recibido quimioterapia neoadyuvante (QTNA) sigue siendo controvertida. El objetivo de este estudio es analizar y comparar resultados oncológicos y las tasas de complicaciones y reintervención en pacientes sometidas a QTNA y un grupo control.MétodosAnálisis observacional retrospectivo de casos-controles. Pacientes con cáncer de mama inter...
Condition: Breast Cancer Interventions: Drug: GDC-0077; Drug: Placebo; Drug: Palbociclib; Drug: Fulvestrant Sponsor: Hoffmann-La Roche Not yet recruiting
Condition: Breast Cancer Interventions: Drug: SAR439859; Drug: letrozole Sponsor: Sanofi Recruiting
Condition: Triple Negative Breast Neoplasms Interventions: Biological: Pembrolizumab; Drug: Olaparib; Drug: Carboplatin; Drug: Gemcitabine Sponsor: Merck Sharp & Dohme Corp. Not yet recruiting
Condition: Breast Cancer Intervention: Other: FR-Mask Sponsor: China Medical University Hospital Recruiting
Conditions: Breast Neoplasm Female; Symptom Cluster; Tai ji Interventions: Other: wait list control; Behavioral: tai chi group Sponsors: Charles Darwin University; The Affiliated Hospital Of Southwest Medical University; The Affiliated Hospital of Putian University; Shenzhen Sixth People's Hospital Not yet recruiting
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8 Interventions: Biological: Pembrolizumab; Drug: Tamoxifen; Drug: Vorinostat Sponsors: University of California, San Francisco; Merck Sharp & Dohme Corp. Not yet recruiting